Raphael Pharmaceutical INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OQB
Raphael Pharmaceutical Inc. announced the voluntary resignations of its Chairman and CFO, along with the appointment of a new CFO.
OQB
Dr. Yehuda Eliya's term as a director of Raphael Pharmaceutical Inc. expired on December 31, 2025, with no reported disagreements.
OQB
Raphael Pharmaceutical Inc. announced a change to its Board of Directors with Dr. Igal Louria Hayon's resignation and Mr. Zvi Laufer Laor's appointment.
OQB
Raphael Pharmaceutical Inc. has completed development of its RaphaWell natural formula for rheumatoid arthritis support and is preparing for a U.S. launch following successful clinical trials.
OQB
Raphael Pharmaceuticals has expanded its board and appointed Ajay Kumar Dhadha as a new director and Chairman, replacing Shlomo Pilo.
OQB
Raphael Pharmaceuticals reports successful proof-of-concept study results for its cannabinoid-based formula in treating Rheumatoid Arthritis, showing significant improvements in patient health parameters.
OQB
Raphael Pharmaceuticals has dismissed its previous auditor, Weinstein International CPA, and appointed Elkana Amitai CPA on a short-term basis, effective September 5, 2024.
OQB
Raphael Pharmaceutical Inc. has amended its articles of incorporation to increase the number of authorized common shares from 21,020,560 to 50,000,000.
OQB
Raphael Pharmaceutical has commenced a proof-of-concept clinical trial in the U.S. to evaluate the efficacy of Cannabigerol in treating Rheumatoid Arthritis.